- €65M investment in Lyon for avian vaccines
- 5,700 sq m facility with 1,000 sq m clean room
- 42 new jobs created, including technicians and managers
- First batches expected by spring 2020
Investment and New Facility
Boehringer Ingelheim is investing €65 million in a new 5,700 sq m building at its Lyon Porte-des-Alpes site. The facility, named F2IVE, will focus on formulating and distributing avian vaccines. It includes 1,000 sq m of clean room space and features an environmentally friendly design.
Rising Demand for Avian Vaccines
With global poultry consumption increasing, the demand for avian vaccines is also rising. The LPA production site in Saint-Priest was projected to reach capacity by 2020, necessitating additional production capabilities. The new facility will house two formulation lines, a multi-format bottle distribution line, and a bag distribution area.
Job Creation and Timeline
The investment will create 42 new jobs, primarily for qualified operations staff such as flow and maintenance managers and production technicians. Earthworks for the high-tech building began in March 2018, with the first vaccine batches expected by spring 2020.
Long-term Commitment
Since acquiring Merial in January 2017, Boehringer Ingelheim has continued to invest in the Lyon region. Over the past 22 years, more than €350 million has been invested in the LPA site. This new investment will eventually triple the site's inactivated vaccine production capacity.
